Aquestive Therapeutics (AQST) Accumulated Expenses (2018 - 2026)

Aquestive Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 4.07% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (up 4.07% YoY), while the FY2025 annual figure was $5.0 million, down 14.86% from the prior year.
• Accumulated Expenses was $3.4 million for Q1 2026 at Aquestive Therapeutics, down from $5.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $8.0 million in Q4 2022 to a low of $3.3 million in Q1 2025.
• Historically, Accumulated Expenses has averaged $5.4 million across 5 years, with a median of $5.0 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses sank 39.46% in 2023, then jumped 33.1% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $8.0 million in 2022, then retreated by 18.45% to $6.5 million in 2023, then retreated by 9.08% to $5.9 million in 2024, then retreated by 14.86% to $5.0 million in 2025, then slumped by 31.42% to $3.4 million in 2026.
• The last three Accumulated Expenses figures came in at $3.4 million (Q1 2026), $5.0 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.